Dementia

Calling All BioXcel Therapeutics, Inc. (BTAI) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!

Retrieved on: 
Thursday, July 13, 2023

Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/btai .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/btai .
  • If you wish to review a copy of the Complaint, you can visit the firm’s site: www.bgandg.com/btai or you may contact Peretz Bronstein, Esq.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Sensi.AI Welcomes Teepa Snow to Advisory Board

Retrieved on: 
Thursday, July 13, 2023

AUSTIN, Texas, July 13, 2023 /PRNewswire/ -- Sensi.AI, a revolutionary 24/7 Virtual Care platform that provides home care agencies data-driven insights and analytics on a senior's physical, emotional, and cognitive needs, today announced the appointment of dementia care pioneer Teepa Snow to its Advisory Board. This new partnership signals a pivotal shift in care delivery and promises significant advancements for individuals living with dementia.

Key Points: 
  • AUSTIN, Texas, July 13, 2023 /PRNewswire/ -- Sensi.AI , a revolutionary 24/7 Virtual Care platform that provides home care agencies data-driven insights and analytics on a senior's physical, emotional, and cognitive needs, today announced the appointment of dementia care pioneer Teepa Snow to its Advisory Board.
  • Snow, renowned for her groundbreaking work with Positive Approach to Care (PAC), joins Sensi.AI in an advisory role, bringing a wealth of experience and an invaluable perspective to the team.
  • Snow's inspirational commitment to transforming dementia care resonates with Sensi's mission of driving innovation and excellence in home care.
  • Snow will contribute essential insights and guidance to Sensi.AI as the company progresses in its pioneering trajectory within the senior care sector.

DAVOS ALZHEIMER’S COLLABORATIVE SHARES ADVANCEMENT OF PREPARING HEALTHCARE SYSTEMS AND INCLUSIVE RESEARCH AT THE 2023 AAIC

Retrieved on: 
Thursday, July 13, 2023

NIMR Africa work: filling the major data gap of dementia/Alzheimer’s as a life course disease; how Africa can lead on this front – Rhoda Au, Davos Alzheimer's Collaborative.

Key Points: 
  • NIMR Africa work: filling the major data gap of dementia/Alzheimer’s as a life course disease; how Africa can lead on this front – Rhoda Au, Davos Alzheimer's Collaborative.
  • Implementation of a smartphone application for precision brain health assessment in a rural low socioeconomic setting: The Bogalusa Heart Study.
  • The Davos Alzheimer’s Collaborative (DAC) is a global effort to spark genuine collaboration among scientists, healthcare providers, government health ministers, philanthropists, and corporate leaders, to speed innovation and stop Alzheimer’s disease.
  • Launched at the World Economic Forum’s 2021 meeting on The Davos Agenda, the Collaborative is committed to a new vision for a collective global response against the challenges Alzheimer’s presents to patients, caregivers and healthcare systems.

BioXcel Therapeutics, Inc: Please contact the Portnoy Law Firm to recover your losses; September 5, 2023 deadline

Retrieved on: 
Wednesday, July 12, 2023

LOS ANGELES, July 12, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI).

Key Points: 
  • LOS ANGELES, July 12, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI).
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 844-767-8529 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

INVESTOR ALERT: Edelson Lechtzin LLP Urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) Shareholders with Substantial Losses to Seek Leadership in the Securities Fraud Class Action

Retrieved on: 
Wednesday, July 12, 2023

Investors who purchased BioXcel common stock may move the Court to appoint them as lead plaintiff, no later than September 5, 2023.

Key Points: 
  • Investors who purchased BioXcel common stock may move the Court to appoint them as lead plaintiff, no later than September 5, 2023.
  • Current holders of BioXcel stock may pursue corporate governance reforms.
  • Please contact Edelson Lechtzin LLP at 844-696-7492 to discuss your investment losses, or by e-mail at [email protected] .
  • On this news, BioXcel’s stock price fell $11.28 per share, or 63.8%, to close at $6.39 per share on June 29, 2023, on unusually heavy trading volume.

BTAI SHAREHOLDER ALERT: Jakubowitz Law Reminds BioXcel Shareholders of a Lead Plaintiff Deadline of September 5, 2023

Retrieved on: 
Wednesday, July 12, 2023

NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI).

Key Points: 
  • NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ: BTAI).
  • To receive updates on the lawsuit, fill out the form:
    The lawsuit seeks to recover losses for shareholders who purchased BioXcel between December 15, 2021 and June 28, 2023.
  • Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until September 5, 2023 to petition the court.
  • Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud.

IGC Reports Financial Results for Fiscal Year Ended March 31, 2023

Retrieved on: 
Wednesday, July 12, 2023

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC), a clinical-stage pharmaceutical company, today announced its financial results for the fiscal year ended March 31, 2023 (“Fiscal 2023”).

Key Points: 
  • IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC), a clinical-stage pharmaceutical company, today announced its financial results for the fiscal year ended March 31, 2023 (“Fiscal 2023”).
  • On March 8, 2023, the Company filed a provisional patent application with the USPTO titled “Composition, Synthesis, and Medical Use of Hybrid Cannabinoid”.
  • Ram Mukunda, CEO of IGC, commented, “Fiscal 2023 was characterized by remarkable growth and progress as we continue to advance our drug formulations through FDA trials.
  • Net loss for Fiscal 2023 was approximately $11.5 million or $0.22 per share, compared to approximately $15 million or $0.30 per share for Fiscal 2022.

Calling All BioXcel Therapeutics, Inc. (BTAI) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!

Retrieved on: 
Wednesday, July 12, 2023

Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/btai .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/btai .
  • If you wish to review a copy of the Complaint, you can visit the firm’s site: www.bgandg.com/btai or you may contact Peretz Bronstein, Esq.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Therapeutic Solutions International Files for Orphan Drug Designation Use of JadiCell Adult Stem Cells for Treatment of Frontotemporal Dementia

Retrieved on: 
Wednesday, July 12, 2023

Therapeutic Solutions International, Inc. (TSOI), a clinical stage regenerative medicine and immunotherapy company, announced today new data and filing with the FDA for Orphan Drug Designation of its JadiCell adult stem cell in the treatment of Frontotemporal Dementia.

Key Points: 
  • Therapeutic Solutions International, Inc. (TSOI), a clinical stage regenerative medicine and immunotherapy company, announced today new data and filing with the FDA for Orphan Drug Designation of its JadiCell adult stem cell in the treatment of Frontotemporal Dementia.
  • This neurodegenerative disease is the leading cause of dementia in patients under 60 years old and to date no therapies have been shown to reduce its progression1.
  • Frontotemporal dementia is caused by a buildup of particular proteins that form clumps inside brain cells, causing brain inflammation and activation of certain immune cells which result in damage to the frontal and temporal lobes.
  • “We are excited that we can begin offering this treatment today based on the established clinical history and safety profile of this immune modulatory cellular therapy.”

Drs. Bradley Bale and Amy Doneen Win Two Awards for Book "Healthy Heart, Healthy Brain"

Retrieved on: 
Wednesday, July 12, 2023

SPOKANE, Wash., July 12, 2023 /PRNewswire/ -- Cardiovascular disease (CVD) prevention specialists Bradley Bale, MD and Amy Doneen, DNP have won gold in the prestigious Nautilus Book Awards for 2023 for their book, " Healthy Heart, Healthy Brain: The Personalized Path to Protect Your Memory, Prevent Heart Attacks, and Strokes, and Avoid Chronic Illness ."

Key Points: 
  • SPOKANE, Wash., July 12, 2023 /PRNewswire/ -- Cardiovascular disease (CVD) prevention specialists Bradley Bale, MD and Amy Doneen, DNP have won gold in the prestigious Nautilus Book Awards for 2023 for their book, " Healthy Heart, Healthy Brain: The Personalized Path to Protect Your Memory, Prevent Heart Attacks, and Strokes, and Avoid Chronic Illness ."
  • Coauthored by Lisa Collier Cool, the book also won the American Society for Journalists and Authors' (ASJA) 2023 June Roth Memorial Award for Outstanding Medical Book.
  • Honoring "Better Books for a Better World" in several categories, the Nautilus Book Awards celebrate visionary books aimed at advancing physical, mental, and spiritual healing through positive social action and individual empowerment.
  • Dr. Doneen is also the medical director of The Prevention Center for Heart & Brain Health in Spokane, Washington.